Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: IPO5P1 (ImmuneEditome ID:100132815)

1. Gene summary of enriched editing regions for IPO5P1

Gene summary

Gene information	Gene symbol	IPO5P1
	Gene ID	100132815
	GeneSynonyms	-
	GeneCytomap	19p12
	GeneType	pseudo
	GeneDescription	-
	GeneModificationdate	20230329
	UniprotID	.
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr19:23257369-23258634:-	ENST00000593576.1	ENSG00000269837.1	IPO5P1	ncRNA_exonic	AluSp,AluSx1,BSR/Beta	chr19:23257369-23258634:-.alignment

Top

2. Tumor-specific enriched editing regions for IPO5P1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
ENSG00000269837.1,IPO5P1	BRCA	EAG	7.7525e-05
ENSG00000269837.1,IPO5P1	COAD	EAG	3.2560e-03
chr19:23257369-23258634:-	KICH	EER	1.8733e-03
ENSG00000269837.1,IPO5P1	KICH	EAG	1.7736e-03
chr19:23257369-23258634:-	KIRC	EER	3.0913e-07
ENSG00000269837.1,IPO5P1	KIRC	EAG	8.8412e-07
chr19:23257369-23258634:-	KIRP	EER	4.5283e-02
ENSG00000269837.1,IPO5P1	KIRP	EAG	2.5218e-03
chr19:23257369-23258634:-	PRAD	EER	7.6051e-05
chr19:23257369-23258634:-	THCA	EER	4.1555e-04
ENSG00000269837.1,IPO5P1	THCA	EAG	7.6713e-09
ENSG00000269837.1,IPO5P1	UCEC	EAG	2.1162e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000269837.1,IPO5P1	BLCA	Path	EAG	2.8225e-03	1.3588e-03	0.1860
ENSG00000269837.1,IPO5P1	KIRC	Path	EAG	3.3529e-02	6.9383e-03	0.1386
chr19:23257369-23258634:-	OV	Cli	EER	5.3644e-03	4.2965e-04	0.2014
ENSG00000269837.1,IPO5P1	THCA	Path	EAG	1.6909e-02	2.5978e-03	0.1351
ENSG00000269837.1,IPO5P1	UCEC	Cli	EAG	3.4322e-03	3.3332e-03	-0.1461

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr19:23257369-23258634:-	BLCA	EER	2.0508e-02	5.5354e-03	7.3703e+01
ENSG00000269837.1,IPO5P1	HNSC	EAG	1.8830e-02	1.3517e-02	1.1165e-03
chr19:23257369-23258634:-	SARC	EER	3.0886e-02	3.6015e-02	1.3179e+02

Top

3. Enriched editing regions and immune related genes for IPO5P1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr19:23257369-23258634:-

GBM

EER

ENSG00000269837,IPO5P1

-0.5265

1.2433e-06

6.3895e-08

-0.4527

T_cells_CD4_memory_activated

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

chr19:23257369-23258634:-

GBM

EER

ENSG00000204650,CRHR1-IT1

-0.4556

7.7627e-05

2.2172e-06

-0.4014

Monocytes

GSVA_HALLMARK_APOPTOSIS

chr19:23257369-23258634:-

GBM

EER

ENSG00000205683,DPF3

0.3530

3.7738e-03

1.8274e-06

0.4044

DDX3X;DGCR8;ELAVL1;FUS;IGF2BP2;NONO;TAF15

T_cells_CD8

GSVA_HALLMARK_NOTCH_SIGNALING

More results

Top

4. Enriched editing regions and immune related splicing for IPO5P1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000269837.1,IPO5P1

BLCA

EAG

ENSG00000139278.5

chr12

75495576:75498720:75498823:75503853

-0.4018

3.3397e-09

1.9856e-16

-0.4550

Dendritic_cells_activated

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

ENSG00000269837.1,IPO5P1

BLCA

EAG

ENSG00000139278.5

chr12

75495576:75495662:75498693:75498717

-0.3857

1.2962e-08

4.6036e-17

-0.4635

Macrophages_M1

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

ENSG00000269837.1,IPO5P1

BLCA

EAG

ENSG00000111679.12

chr12

6951261:6951520:6951608:6951731

-0.3329

1.0842e-07

7.1313e-15

-0.4676

PTPN6

Dendritic_cells_activated

GSVA_HALLMARK_COMPLEMENT

ENSG00000269837.1,IPO5P1

BLCA

EAG

ENSG00000177479.15

chr3

48924717:48924971:48927461:48927725

-0.3085

4.4141e-07

1.5964e-11

-0.4271

T_cells_CD4_memory_activated

GSVA_HALLMARK_UV_RESPONSE_UP

ENSG00000269837.1,IPO5P1

BLCA

EAG

ENSG00000143933.12

chr2

47170733:47170764:47172413:47172459

-0.3154

5.0926e-07

3.6688e-11

-0.4135

T_cells_CD4_naive

GSVA_HALLMARK_UV_RESPONSE_UP

ENSG00000269837.1,IPO5P1

BLCA

EAG

ENSG00000132694.14

chr1

156937248:156937496:156938417:156938513

-0.3190

6.2853e-07

1.4448e-11

-0.4110

ARHGEF11

Dendritic_cells_activated

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

ENSG00000269837.1,IPO5P1

BLCA

EAG

ENSG00000178149.12

chr3

49015487:49015872:49015972:49016033

-0.3294

6.3192e-06

7.3624e-13

-0.4016

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_COMPLEMENT

ENSG00000269837.1,IPO5P1

BLCA

EAG

ENSG00000182473.16

chr17

76089174:76091235:76094413:76094489

-0.2776

7.0238e-06

1.9018e-10

-0.4142

EXOC7

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_UV_RESPONSE_UP

ENSG00000269837.1,IPO5P1

BLCA

EAG

ENSG00000178149.12

chr3

49015487:49015707:49015803:49015872

-0.3119

2.4284e-05

9.0336e-13

-0.4002

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_COMPLEMENT

ENSG00000269837.1,IPO5P1

GBM

EAG

ENSG00000197343.6

chr7

99562367:99562494:99563187:99563266:99563862:99564705

-0.3255

3.3546e-03

1.3309e-06

-0.4078

T_cells_follicular_helper

GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE

More results

Top

5. Enriched editing regions and immune infiltration for IPO5P1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000269837.1,IPO5P1	ACC	EAG	T_cells_gamma_delta	6.4403e-05	0.7236
chr19:23257369-23258634:-	BLCA	EER	T_cells_CD4_naive	2.2549e-03	-0.2526
ENSG00000269837.1,IPO5P1	BLCA	EAG	Macrophages_M1	5.2832e-07	0.2871
chr19:23257369-23258634:-	BRCA	EER	T_cells_CD8	1.2290e-02	0.1149
ENSG00000269837.1,IPO5P1	BRCA	EAG	T_cells_regulatory_(Tregs)	3.1725e-02	-0.0745
ENSG00000269837.1,IPO5P1	CESC	EAG	Dendritic_cells_activated	3.9245e-04	0.2925
ENSG00000269837.1,IPO5P1	CHOL	EAG	Macrophages_M1	1.2998e-02	0.5448
chr19:23257369-23258634:-	COAD	EER	Eosinophils	4.4886e-02	0.2063
ENSG00000269837.1,IPO5P1	COAD	EAG	Mast_cells_resting	1.6351e-02	0.1839
ENSG00000269837.1,IPO5P1	DLBC	EAG	Neutrophils	1.8321e-04	0.5580
ENSG00000269837.1,IPO5P1	ESCA	EAG	Plasma_cells	2.0096e-02	-0.2698
chr19:23257369-23258634:-	GBM	EER	Dendritic_cells_activated	6.6030e-03	0.2371
ENSG00000269837.1,IPO5P1	GBM	EAG	Monocytes	2.4149e-03	0.2428
ENSG00000269837.1,IPO5P1	HNSC	EAG	NK_cells_resting	2.0046e-02	0.2519
chr19:23257369-23258634:-	KICH	EER	Mast_cells_activated	1.6316e-02	0.3686
chr19:23257369-23258634:-	KIRC	EER	T_cells_regulatory_(Tregs)	1.6263e-02	0.1830
ENSG00000269837.1,IPO5P1	KIRC	EAG	T_cells_CD4_memory_resting	2.2391e-02	-0.1377
ENSG00000269837.1,IPO5P1	KIRP	EAG	T_cells_CD4_memory_resting	1.1803e-02	-0.1545
chr19:23257369-23258634:-	LAML	EER	T_cells_CD4_memory_activated	1.2262e-03	-0.4285
ENSG00000269837.1,IPO5P1	LAML	EAG	Monocytes	4.4327e-03	0.2837
chr19:23257369-23258634:-	LGG	EER	Neutrophils	2.4184e-02	-0.1116
ENSG00000269837.1,IPO5P1	LGG	EAG	Dendritic_cells_activated	1.4229e-04	0.1664
chr19:23257369-23258634:-	LIHC	EER	Macrophages_M2	9.2084e-03	-0.2877
ENSG00000269837.1,IPO5P1	LIHC	EAG	Macrophages_M1	8.2246e-04	0.2128
chr19:23257369-23258634:-	LUAD	EER	Macrophages_M0	3.1047e-02	-0.1811
ENSG00000269837.1,IPO5P1	LUAD	EAG	T_cells_CD4_memory_activated	4.6047e-03	0.1613
chr19:23257369-23258634:-	LUSC	EER	B_cells_memory	1.4474e-02	0.1993
ENSG00000269837.1,IPO5P1	LUSC	EAG	T_cells_follicular_helper	2.4556e-02	-0.1470
chr19:23257369-23258634:-	MESO	EER	T_cells_regulatory_(Tregs)	4.1457e-02	-0.3878
ENSG00000269837.1,IPO5P1	MESO	EAG	Dendritic_cells_activated	1.1306e-02	0.3197
chr19:23257369-23258634:-	OV	EER	B_cells_memory	2.4851e-02	0.1470
ENSG00000269837.1,IPO5P1	OV	EAG	T_cells_CD8	1.0978e-05	0.2572
chr19:23257369-23258634:-	PAAD	EER	NK_cells_resting	4.4922e-03	0.5297
ENSG00000269837.1,IPO5P1	PAAD	EAG	Macrophages_M1	2.1811e-02	0.2628
chr19:23257369-23258634:-	PCPG	EER	Mast_cells_activated	2.1008e-04	0.3792
ENSG00000269837.1,IPO5P1	PCPG	EAG	B_cells_memory	3.0788e-03	0.2232
chr19:23257369-23258634:-	PRAD	EER	T_cells_gamma_delta	9.4952e-04	0.1774
ENSG00000269837.1,IPO5P1	PRAD	EAG	Macrophages_M1	8.0269e-05	0.1760
chr19:23257369-23258634:-	SARC	EER	T_cells_gamma_delta	1.4556e-03	0.3897
ENSG00000269837.1,IPO5P1	SKCM	EAG	Mast_cells_resting	1.3077e-02	-0.2131
ENSG00000269837.1,IPO5P1	STAD	EAG	T_cells_CD8	3.1070e-02	0.1444
chr19:23257369-23258634:-	TGCT	EER	Macrophages_M2	1.3571e-05	-0.4682
ENSG00000269837.1,IPO5P1	TGCT	EAG	Macrophages_M2	1.0296e-08	-0.4548
chr19:23257369-23258634:-	THCA	EER	T_cells_regulatory_(Tregs)	7.8691e-04	0.1767
ENSG00000269837.1,IPO5P1	THCA	EAG	Macrophages_M2	1.0114e-04	-0.1737
chr19:23257369-23258634:-	THYM	EER	T_cells_regulatory_(Tregs)	1.0881e-02	-0.3408
ENSG00000269837.1,IPO5P1	THYM	EAG	Macrophages_M1	1.1800e-06	0.4368
chr19:23257369-23258634:-	UCEC	EER	B_cells_naive	1.1813e-02	-0.3285
ENSG00000269837.1,IPO5P1	UCS	EAG	T_cells_CD4_memory_activated	1.6739e-03	0.4177

Top

6. Enriched editing regions and immune gene sets for IPO5P1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
ENSG00000269837.1,IPO5P1	BLCA	EAG	2.9943e-03		8.7465e-17	0.4591
ENSG00000269837.1,IPO5P1	BRCA	EAG	2.6465e-02		1.5051e-03	0.1099

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000269837.1,IPO5P1	THYM	EAG	6.4423e-04	-0.3149	8.2871e-07	-0.4424	3.0826e-02	0.2024	3.6513e-04	0.3281

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000269837.1,IPO5P1	ACC	GSVA_HALLMARK_KRAS_SIGNALING_UP	EAG	9.3921e-03	0.5188
chr19:23257369-23258634:-	BLCA	GSVA_HALLMARK_MYOGENESIS	EER	2.9212e-05	0.3408
ENSG00000269837.1,IPO5P1	BLCA	GSVA_HALLMARK_APICAL_JUNCTION	EAG	1.0828e-17	0.4710
chr19:23257369-23258634:-	BRCA	GSVA_HALLMARK_APOPTOSIS	EER	1.2299e-04	0.1755
ENSG00000269837.1,IPO5P1	BRCA	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	4.8542e-10	0.2136
chr19:23257369-23258634:-	CESC	GSVA_HALLMARK_MYC_TARGETS_V1	EER	3.7360e-02	-0.2924
ENSG00000269837.1,IPO5P1	CESC	GSVA_HALLMARK_COMPLEMENT	EAG	2.0887e-04	0.3053
ENSG00000269837.1,IPO5P1	COAD	GSVA_HALLMARK_HEME_METABOLISM	EAG	1.8042e-04	0.2834
ENSG00000269837.1,IPO5P1	ESCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	2.9772e-02	0.2528
chr19:23257369-23258634:-	ESCA	GSVA_HALLMARK_SPERMATOGENESIS	EER	3.9578e-02	-0.2836
chr19:23257369-23258634:-	GBM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	5.3077e-06	0.3873
ENSG00000269837.1,IPO5P1	GBM	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	8.5577e-08	0.4152
chr19:23257369-23258634:-	HNSC	GSVA_HALLMARK_G2M_CHECKPOINT	EER	1.1139e-03	-0.4804
ENSG00000269837.1,IPO5P1	HNSC	GSVA_HALLMARK_APICAL_JUNCTION	EAG	1.3004e-04	0.4032
chr19:23257369-23258634:-	KICH	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	2.8951e-02	0.3373
chr19:23257369-23258634:-	KIRC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.1311e-06	0.3612
ENSG00000269837.1,IPO5P1	KIRC	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	5.4576e-03	0.1671
ENSG00000269837.1,IPO5P1	KIRP	GSVA_HALLMARK_GLYCOLYSIS	EAG	4.7100e-04	0.2133
chr19:23257369-23258634:-	KIRP	GSVA_HALLMARK_P53_PATHWAY	EER	8.5150e-03	0.2308
ENSG00000269837.1,IPO5P1	LAML	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	6.4900e-04	0.3369
ENSG00000269837.1,IPO5P1	LGG	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	1.6769e-17	0.3622
chr19:23257369-23258634:-	LGG	GSVA_HALLMARK_MYOGENESIS	EER	2.4966e-07	0.2520
chr19:23257369-23258634:-	LIHC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.3829e-02	0.2726
ENSG00000269837.1,IPO5P1	LIHC	GSVA_HALLMARK_HEME_METABOLISM	EAG	8.7887e-06	0.2803
ENSG00000269837.1,IPO5P1	LUAD	GSVA_HALLMARK_APOPTOSIS	EAG	4.0687e-08	0.3069
chr19:23257369-23258634:-	LUAD	GSVA_HALLMARK_P53_PATHWAY	EER	6.5561e-04	0.2826
ENSG00000269837.1,IPO5P1	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	9.7507e-04	0.2142
chr19:23257369-23258634:-	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	7.2839e-04	0.2729
chr19:23257369-23258634:-	MESO	GSVA_HALLMARK_SPERMATOGENESIS	EER	2.4423e-02	-0.4243
ENSG00000269837.1,IPO5P1	MESO	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.0660e-02	-0.3222
chr19:23257369-23258634:-	OV	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	1.4686e-02	0.1597
ENSG00000269837.1,IPO5P1	OV	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.6195e-10	0.3670
ENSG00000269837.1,IPO5P1	PAAD	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.8340e-02	0.2700
chr19:23257369-23258634:-	PCPG	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	8.9116e-03	0.2727
ENSG00000269837.1,IPO5P1	PCPG	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	5.7122e-05	0.3002
chr19:23257369-23258634:-	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.0443e-06	-0.2486
ENSG00000269837.1,IPO5P1	PRAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.0730e-04	0.1729
ENSG00000269837.1,IPO5P1	READ	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	4.2171e-03	0.3404
chr19:23257369-23258634:-	READ	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	9.9191e-04	0.5069
chr19:23257369-23258634:-	SARC	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	3.6121e-02	0.2625
ENSG00000269837.1,IPO5P1	SARC	GSVA_HALLMARK_COAGULATION	EAG	2.9205e-02	0.1725
chr19:23257369-23258634:-	SKCM	GSVA_HALLMARK_HEME_METABOLISM	EER	4.1454e-02	0.3019
ENSG00000269837.1,IPO5P1	SKCM	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	2.3557e-04	0.3115
ENSG00000269837.1,IPO5P1	STAD	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EAG	3.2386e-05	0.2745
chr19:23257369-23258634:-	TGCT	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	2.2788e-04	0.4034
ENSG00000269837.1,IPO5P1	TGCT	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	7.2068e-06	0.3642
chr19:23257369-23258634:-	THCA	GSVA_HALLMARK_GLYCOLYSIS	EER	3.0119e-07	0.2668
ENSG00000269837.1,IPO5P1	THCA	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EAG	3.4760e-08	0.2445
chr19:23257369-23258634:-	THYM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.5688e-05	-0.5468
ENSG00000269837.1,IPO5P1	THYM	GSVA_HALLMARK_SPERMATOGENESIS	EAG	2.4334e-09	-0.5227
chr19:23257369-23258634:-	UCEC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.2863e-03	-0.4126
ENSG00000269837.1,IPO5P1	UCEC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	7.9162e-03	0.2086
ENSG00000269837.1,IPO5P1	UCS	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	5.1822e-03	0.3752
chr19:23257369-23258634:-	UCS	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	4.5947e-02	0.4400
ENSG00000269837.1,IPO5P1	UVM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	4.3661e-02	0.3481

Top

7. Enriched editing regions and drugs for IPO5P1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr19:23257369-23258634:-	BLCA	CGP.60474	EER	1.6210e-04	-0.3093
ENSG00000269837.1,IPO5P1	BLCA	CGP.60474	EAG	1.0439e-18	-0.4837
chr19:23257369-23258634:-	BRCA	ABT.263	EER	2.7861e-02	0.1012
ENSG00000269837.1,IPO5P1	BRCA	Methotrexate	EAG	2.8892e-06	0.1614
ENSG00000269837.1,IPO5P1	CESC	CI.1040	EAG	1.1266e-04	-0.3173
ENSG00000269837.1,IPO5P1	CHOL	BI.2536	EAG	1.3403e-02	0.5428
ENSG00000269837.1,IPO5P1	COAD	Bexarotene	EAG	1.5407e-03	-0.2411
chr19:23257369-23258634:-	COAD	BMS.708163	EER	4.3229e-02	0.2079
ENSG00000269837.1,IPO5P1	DLBC	Cytarabine	EAG	7.1592e-03	0.4188
chr19:23257369-23258634:-	ESCA	AZD.2281	EER	3.7409e-02	-0.2867
ENSG00000269837.1,IPO5P1	ESCA	CHIR.99021	EAG	5.6417e-03	-0.3188
ENSG00000269837.1,IPO5P1	GBM	BI.D1870	EAG	1.3572e-10	0.4881
chr19:23257369-23258634:-	GBM	BIRB.0796	EER	1.7197e-04	0.3237
chr19:23257369-23258634:-	HNSC	BX.795	EER	1.3123e-04	0.5504
ENSG00000269837.1,IPO5P1	HNSC	AZD6244	EAG	4.8003e-05	-0.4260
ENSG00000269837.1,IPO5P1	KICH	Cisplatin	EAG	3.4526e-03	-0.4020
chr19:23257369-23258634:-	KICH	Erlotinib	EER	2.9005e-05	-0.5979
ENSG00000269837.1,IPO5P1	KIRC	Cyclopamine	EAG	3.2273e-03	-0.1773
chr19:23257369-23258634:-	KIRC	FH535	EER	1.3081e-02	0.1889
ENSG00000269837.1,IPO5P1	KIRP	BI.2536	EAG	6.7514e-05	0.2423
chr19:23257369-23258634:-	KIRP	AZD6244	EER	6.3011e-03	-0.2393
ENSG00000269837.1,IPO5P1	LAML	Embelin	EAG	2.3729e-04	0.3614
ENSG00000269837.1,IPO5P1	LGG	Epothilone.B	EAG	9.2326e-18	0.3649
chr19:23257369-23258634:-	LGG	BAY.61.3606	EER	3.3664e-06	0.2277
ENSG00000269837.1,IPO5P1	LIHC	Etoposide	EAG	3.5165e-03	0.1862
chr19:23257369-23258634:-	LIHC	Methotrexate	EER	4.9276e-03	-0.3153
chr19:23257369-23258634:-	LUAD	AS601245	EER	2.3585e-03	-0.2532
ENSG00000269837.1,IPO5P1	LUAD	CI.1040	EAG	1.2937e-05	-0.2461
chr19:23257369-23258634:-	LUSC	Cyclopamine	EER	5.1364e-05	-0.3254
ENSG00000269837.1,IPO5P1	LUSC	CI.1040	EAG	3.1552e-04	-0.2335
ENSG00000269837.1,IPO5P1	MESO	BIRB.0796	EAG	1.9357e-03	0.3862
chr19:23257369-23258634:-	MESO	Epothilone.B	EER	1.8343e-03	-0.5625
chr19:23257369-23258634:-	OV	Bryostatin.1	EER	2.4584e-04	-0.2380
ENSG00000269837.1,IPO5P1	OV	CI.1040	EAG	1.3895e-08	-0.3282
ENSG00000269837.1,IPO5P1	PAAD	GW.441756	EAG	1.8789e-02	0.2690
chr19:23257369-23258634:-	PAAD	A.770041	EER	7.4247e-03	-0.5035
chr19:23257369-23258634:-	PCPG	AZD6244	EER	8.5841e-04	-0.3435
ENSG00000269837.1,IPO5P1	PCPG	BI.2536	EAG	2.9409e-09	0.4309
ENSG00000269837.1,IPO5P1	PRAD	Epothilone.B	EAG	4.8041e-07	0.2235
chr19:23257369-23258634:-	PRAD	BMS.536924	EER	3.9413e-09	-0.3111
ENSG00000269837.1,IPO5P1	READ	JW.7.52.1	EAG	3.3645e-03	-0.3482
chr19:23257369-23258634:-	READ	BMS.708163	EER	1.9958e-02	-0.3713
chr19:23257369-23258634:-	SARC	GSK269962A	EER	1.7710e-03	0.3833
ENSG00000269837.1,IPO5P1	SARC	GNF.2	EAG	4.0802e-06	-0.3551
chr19:23257369-23258634:-	SKCM	AZ628	EER	2.1014e-02	0.3394
ENSG00000269837.1,IPO5P1	SKCM	MG.132	EAG	4.3608e-05	-0.3442
ENSG00000269837.1,IPO5P1	STAD	AZ628	EAG	6.9500e-03	-0.1803
chr19:23257369-23258634:-	STAD	BMS.708163	EER	5.8289e-03	-0.2076
chr19:23257369-23258634:-	TGCT	AZD8055	EER	1.6470e-04	-0.4115
ENSG00000269837.1,IPO5P1	TGCT	AP.24534	EAG	1.3152e-04	-0.3133
chr19:23257369-23258634:-	THCA	Embelin	EER	1.3139e-08	0.2948
ENSG00000269837.1,IPO5P1	THCA	CI.1040	EAG	1.4661e-11	-0.2970
chr19:23257369-23258634:-	THYM	BMS.536924	EER	1.5654e-05	-0.5468
ENSG00000269837.1,IPO5P1	THYM	ABT.263	EAG	4.0804e-11	0.5687
chr19:23257369-23258634:-	UCEC	JNK.9L	EER	1.2495e-03	0.4136
ENSG00000269837.1,IPO5P1	UCEC	Bicalutamide	EAG	6.1020e-03	-0.2153
ENSG00000269837.1,IPO5P1	UCS	AG.014699	EAG	1.4962e-02	0.3295
chr19:23257369-23258634:-	UCS	ABT.263	EER	1.0964e-02	0.5430
ENSG00000269837.1,IPO5P1	UVM	AZD8055	EAG	6.6001e-03	0.4569

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType